- Open Access
A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin-fixed paraffin-embedded postmortem Alzheimer's brain tissues
Alzheimer's Research & Therapyvolume 5, Article number: 30 (2013)
Recently, a significant association was identified between a rare rs75932628-T variant encoding R47H in the TREM2 gene and an increased risk for Alzheimer's disease (AD) [1, 2]. TREM2 forms a signaling complex with DAP12 expressed on monocytes/macrophages, dendritic cells, osteoclasts, and microglia. Loss-of-function mutations in either DAP12 or TREM2 are identified in patients with Nasu-Hakola disease, a rare autosomal recessive disorder characterized by presenile dementia and multifocal bone cysts. TREM2 binds to bacterial components and Hsp60, although endogenous ligands remain unknown. R47H located within the extracellular immunoglobulin-like domain of TREM2 possibly causes a reduced affinity of TREM2 for putative ligands. Knockdown of TREM2 on mouse microglia inhibits phagocytosis of apoptotic neurons and stimulates production of tumor necrosis factor-alpha (TNFα) and interleukin-1 beta (IL-1β), suggesting a pivotal role for TREM2 in the clearance of damaged neural tissues to resolve damage-induced inflammation. TREM2 is upregulated in amyloid plaque-associated microglia in mouse models of AD, suggesting an active role for TREM2 in the clearance of deposited amyloid-β by microglia. However, the precise pathological role of TREM2-expressing microglia in AD brains remains unknown.
By immunohistochemistry (IHC), we studied the expression of TREM2 in serial sections of formalin-fixed paraffin-embedded tissues of the frontal cortex and the hippocampus derived from five patients with AD, four patients with amyotrophic lateral sclerosis, and four neurologically normal control subjects. Written informed consent was obtained from all of the cases. The ethics committee of the corresponding institutions approved the present study. The tissue sections were treated for antigen retrieval in 10 mM citrate sodium buffer, pH 6.0, at 110°C for 15 minutes in a temperature-controlled pressure chamber (Biocare Medical, Concord, CA, USA). First, we evaluated the specificity of commercially available anti-TREM2 antibodies, such as HPA010917 (Sigma-Aldrich, St. Louis, MO, USA), AF1828 (R&D Systems, Inc., Minneapolis, MN, USA), 2B5 (Novus Biologicals, Inc., Littleton, CO, USA), bs-2723R (Bioss, Woburn, MA, USA), PA5-18763 (Thermo Fisher Scientific Inc., Waltham, MA, USA), ab69405 (Abcam, Cambridge, UK), and ab85851 (Abcam) by Western blot of recombinant human TREM2 protein expressed in HEK293 cells. Only HPA010917, AF1828, and 2B5, but not others, reacted with TREM2 on the blot (Figure 1). Next, we studied TREM2 expression in spleen, bone marrow, and the brain by IHC with HPA010917, AF1828, and 2B5. Only HPA010917 labeled monocytes/macrophages, dendritic cells, and osteoclasts (Figure 2a,b). Thus, onlyHPA010917 satisfied the specificity and the reactivity toTREM2 both in vitro and in vivo. By IHC withHPA010917, we found an accumulation of Iba1- and DA12-immunoreactive microglia, but Iba1-, HLA-DR-, CD68-, or DAP12-immunoreactive microglia did not express TREM2 in any of the cases examined (Figures 2c,d and 3a-f). In contrast, TREM2 was identified in small subpopulations of intravascular monocytes/macrophages and neurons and was totally absorbed by preincubation with recombinant protein (Figures 2c-f and 3b).
Here we found that Iba1-immunoreactive microglia do not express TREM2 in AD and control brains. Previous studies by IHC with uncharacterized antibodies showed that microglia express TREM2 in the mouse and human cerebral cortex, where it is located in the Golgi complex . Although the possibility exists that neuronal staining of TREM2 reflects immunoreactivity of cross-reactive proteins, the validation requires the development of additional antibodies highly specific for distinct epitopes of TREM2. Not all microglia in the mouse brain express TREM2, and its levels are reduced in cultured microglia by exposure to lipopolysaccharide. Microglial phenotype is changeable from a proinflammatory/neurotoxic (M1) trait to an anti-inflammatory/neuroprotective (M2) trait in response to disturbances of brain homeostasis, suggesting that TREM2 expression on microglia is a transient event in vivo, depending on their microenvironment.
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K: Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013, 368: 107-116. 10.1056/NEJMoa1211103.
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis Group: TREM2 variants in Alzheimer's disease. N Engl J Med. 2013, 368: 117-127. 10.1056/NEJMoa1211851.
Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, Colonna M, Panina P, Meldolesi J: Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci. 2004, 20: 2617-2628. 10.1111/j.1460-9568.2004.03729.x.
This work was supported by grants from the Genome Research Center (GRC) Project and the Grant-in-Aid (C25430054), of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.
The authors declare that they have no competing interests.